Dave Lemus steps down as COO and continues cooperation in an advisory role

Planegg - Medigene AG (FSE: MDG1, Prime Standard, TecDAX) today announced today that the Company's Chief Operating Officer (COO), Dave Lemus, leaves the Company's Executive Management Board, and transitions into a consulting role to Medigene's Supervisory and Management Boards.

Mr. Lemus has served as the Company's COO since the beginning of 2016, stepping down from his previous role of Supervisory Board Vice Chairman held since July 2013. He also assumed the interim functional responsibilities as Chief Financial Officer (CFO) during the previous year until Dr. Thomas Taapken was appointed as CFO in January 2017.

The Chairman of the Supervisory Board of Medigene AG, Prof. Horst Domdey, stated: "On behalf of the Supervisory Board I want to thank Dave Lemus for his invaluable contributions over the past years in his capacity as a member of both the Supervisory and Management Boards. We are extremely grateful he was able to step down from his position in the Supervisory Board onto the Management Board last year at a transformative time when it was critically needed. We are very appreciative of his contributions, particularly of his involvement in the bluebird deal successfully concluded together with the Medigene team last year. We look forward to continued interaction with him in his new role advising the Company's Boards on special projects."

Commenting, Dave Lemus said, "Since my involvement with Medigene on their Supervisory Board in the last years, I have been very pleased to have been part of Medigene's transformation into the leading immunotherapy company that it is has now become. I look forward to contributing further to Medigene in a more flexible role based in the U.S., advising the Company on projects of strategic importance going forward".

About Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, TecDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in clinical and pre-clinical development.

For more information, please visit www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.